Conclusion First
The numbers from all three companies are not bad.
But whether investors can confidently bid the stocks higher is a different question.
| Company | First impression | What the market watches |
|---|---|---|
| Timee | High profitability despite a six-month irregular fiscal period | GMV, utilization, advance payments, and working capital |
| Visional | BizReach remains strong, HRMOS grows | balance between high-profit HR Tech and Incubation losses |
| Ain HD | Sales and profit expanded sharply through M&A | earnings quality and leverage after Sakura Pharmacy integration |
These three companies show what the Japanese market is currently rewarding and questioning.
High growth is not enough. High profitability is not enough. Growth must convert into cash and capital efficiency.
Main Figures
| Company | Period | Revenue | Operating profit | Net income | Note |
|---|---|---|---|---|---|
| Timee | FY2026/4 | 21.006 billion yen | 3.812 billion yen | 2.439 billion yen | six-month irregular period due to fiscal year change |
| Visional | FY2026/7 3Q cumulative | 73.157 billion yen | 19.612 billion yen | 14.214 billion yen | revenue +24.3%, operating profit +12.2% |
| Ain HD | FY2026/4 | 647.834 billion yen | 29.832 billion yen | 17.264 billion yen | revenue +41.8%, operating profit +76.8% |
Ain HD looks strongest in simple growth-rate terms. Visional remains highly profitable. Timee is hard to compare due to the irregular six-month period, but the operating margin is high.
The deeper reading is more nuanced.
Timee: From Growth Stock to Labor-Liquidity Infrastructure
Timee's FY2026/4 results cover the six months from November 1, 2025 to April 30, 2026 due to a fiscal year change.
| Item | FY2026/4 |
|---|---|
| Revenue | 21.006 billion yen |
| Operating profit | 3.812 billion yen |
| Ordinary profit | 3.760 billion yen |
| Net income | 2.439 billion yen |
| Operating margin | 18.1% |
| Operating cash flow | 1.283 billion yen |
| Cash and equivalents | 16.530 billion yen |
Operational KPIs are the key:
- registered workers: more than 14.2 million
- registered client business locations: more than 465,000
- GMV: 69.475 billion yen
- utilization rate: 85.9%
Timee looks less like a job-ad company and more like infrastructure for short-time labor liquidity.
The risk is working capital. As the business expands, advance payments for wages can weigh on operating cash flow.
The next forecast range is revenue of 47.613 billion to 48.823 billion yen and operating profit of 8.821 billion to 9.746 billion yen. The market will watch not just the top or bottom of the range, but whether GMV, utilization, advance payments, and operating cash flow hold together.
Visional: Strong BizReach, Growing HRMOS, High Expectations
Visional's FY2026/7 third-quarter cumulative results were:
| Item | FY2026/7 3Q cumulative | YoY |
|---|---|---|
| Revenue | 73.157 billion yen | +24.3% |
| Operating profit | 19.612 billion yen | +12.2% |
| Ordinary profit | 21.438 billion yen | +17.2% |
| Net income | 14.214 billion yen | +13.2% |
| Equity ratio | 72.5% | high |
BizReach remains the core.
BizReach revenue was 59.714 billion yen, and operating profit before corporate cost allocation was 25.479 billion yen. The number of cumulative client companies exceeded 43,900, and searchable members exceeded 3.42 million.
HRMOS is also growing. HRMOS ARR was 9.486 billion yen, up 171.9% from the prior-year-end level. Active client companies reached 10,262, and the 12-month average churn rate was 0.48%.
But ARPU fell 39.3% to 77,039 yen. User expansion is strong, but unit price is falling. That may reflect customer-base expansion or product mix, but investors need to watch monetization.
Incubation is another issue. The Incubation segment posted revenue of 3.963 billion yen and a segment loss of 1.558 billion yen. The strategy of using HR Tech profit to fund new areas is understandable, but the market will require a path from losses to future earnings.
Visional is a good company. The market already knows that.
Ain Holdings: M&A Growth and a Heavier Balance Sheet
Ain Holdings reported FY2026/4 revenue of 647.834 billion yen and operating profit of 29.832 billion yen.
| Item | FY2026/4 | YoY |
|---|---|---|
| Revenue | 647.834 billion yen | +41.8% |
| Operating profit | 29.832 billion yen | +76.8% |
| Ordinary profit | 28.414 billion yen | +57.2% |
| Net income | 17.264 billion yen | +86.4% |
| Operating cash flow | 30.872 billion yen | +7.726 billion yen |
| Equity ratio | 31.2% | down from 45.7% |
The numbers are strong.
The pharmacy business generated revenue of 556.424 billion yen and segment profit of 35.760 billion yen. Retail also grew to revenue of 80.255 billion yen and segment profit of 6.528 billion yen.
The big driver was consolidation of the Sakura Pharmacy group.
But M&A has a cost. Total assets rose to 509.647 billion yen, and the equity ratio fell to 31.2%. Short- and long-term borrowings were 171.854 billion yen. Debt repayment years were 5.6 years, and the interest coverage ratio declined to 14.3 times.
These are not necessarily bad numbers, but the balance sheet is clearly heavier.
Net income also included about 4.0 billion yen of deferred tax asset impact related to Sakura Pharmacy's better-than-expected earnings improvement. For the next fiscal year, the company forecasts revenue of 721.5 billion yen and operating profit of 32.5 billion yen, but net income of 15.0 billion yen, down 13.1%.
The market will now focus less on size expansion itself and more on whether capital efficiency can be maintained after integration.
What These Three Show
| Evaluation axis | Timee | Visional | Ain HD |
|---|---|---|---|
| Growth | GMV and user base | BizReach and HRMOS | M&A-driven scale |
| Margin | High, but working capital matters | High profit with investment losses | Improved, but M&A-heavy |
| Cash | advance payments can weigh | strong balance sheet | strong operating cash flow, heavy investing cash flow |
| Risks | ad efficiency, regulation, advances | high expectations, ARPU decline, investment losses | borrowings, integration risk, drug-price revisions |
| Market question | Is growth quality intact? | Can the valuation stay high? | Can M&A burden be absorbed? |
The market is no longer satisfied with sales growth alone.
For growth stocks, advertising efficiency and margin matter. For SaaS, ARR, ARPU, and churn matter. For M&A companies, operating cash flow and debt burden matter.
Good numbers are only the starting point.
KPIs to Watch Next
| Company | Next KPIs |
|---|---|
| Timee | GMV, utilization rate, registered workers, client locations, advance payments, operating cash flow |
| Visional | BizReach revenue, HRMOS ARR, ARPU, churn rate, Incubation losses |
| Ain HD | Sakura Pharmacy integration effect, operating cash flow, borrowings, equity ratio, dispensing-fee and drug-price revision impact |
The most important gap is between the growth story and actual cash.
If a company grows but cash is weak, the market becomes skeptical. If profit is strong but M&A makes the balance sheet heavy, valuation multiples become harder to expand.
In this market, sales matter less than profit, and profit matters less than cash.
Sources and Notes
This article is an investment strategy note based on the companies' disclosed earnings materials for Timee, Visional, and Ain Holdings. It is not a recommendation to buy or sell any security.